RZL 012

Drug Profile

RZL 012

Alternative Names: RZL012

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Raziel Therapeutics
  • Developer Raziel Therapeutics; Yissum Research Development Company
  • Class Carbazoles; Obesity therapies; Thermogenics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adiposis-dolorosa; Lipoedema; Obesity

Most Recent Events

  • 01 May 2018 Phase-II clinical trials in Adiposis dolorosa in USA (SC) (NCT03492840)
  • 01 May 2018 Phase-II clinical trials in Lipoedema in USA (SC) (NCT03492840)
  • 10 Apr 2018 Raziel Therapeutics plans a phase II trial for Lipoedema and Adiposis dolorosa in USA (SC) (NCT03492840)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top